Qualigen Short Long Term Debt vs Long Term Debt Analysis

QLGN Stock

USD 4.47 0.31 6.49%

Qualigen Therapeutics financial indicator trend analysis is much more than just breaking down Qualigen Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Qualigen Therapeutics is a good investment. Please check the relationship between Qualigen Therapeutics Short Long Term Debt and its Long Term Debt accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Qualigen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.

Short Long Term Debt vs Long Term Debt

Short Long Term Debt vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Qualigen Therapeutics Short Long Term Debt account and Long Term Debt. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Qualigen Therapeutics' Short Long Term Debt and Long Term Debt is 0.43. Overlapping area represents the amount of variation of Short Long Term Debt that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Qualigen Therapeutics, assuming nothing else is changed. The correlation between historical values of Qualigen Therapeutics' Short Long Term Debt and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt of Qualigen Therapeutics are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Short Long Term Debt i.e., Qualigen Therapeutics' Short Long Term Debt and Long Term Debt go up and down completely randomly.

Correlation Coefficient

0.43

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Short Long Term Debt

The total of a company's short-term and long-term borrowings.

Long Term Debt

Long-term debt is a debt that Qualigen Therapeutics has held for over one year. Long-term debt appears on Qualigen Therapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Qualigen Therapeutics balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most indicators from Qualigen Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Qualigen Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Qualigen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.As of the 27th of November 2024, Selling General Administrative is likely to grow to about 7.3 M, while Tax Provision is likely to drop (5 K).

	2023	2024 (projected)
Depreciation And Amortization	4.5K	4.3K
Interest Income	141.5K	86.2K

Depreciation And Amortization Interest Income

Qualigen Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment	Other Liab	Net Tangible Assets	Net Receivables
Total Assets		0.46	0.18	0.92	0.05	-0.89	0.22	-0.4	0.92	0.05	0.0	0.37	0.92	0.15	-0.36	-0.14	0.32	0.11	0.2	-0.28	0.97	-0.32	-0.19	-0.29	0.64	0.19
Other Current Liab	0.46		0.89	0.08	0.61	-0.08	-0.35	-0.41	0.13	0.63	-0.19	0.51	0.13	-0.34	0.12	0.53	0.77	0.48	0.89	0.13	0.29	0.3	0.29	0.18	0.62	-0.44
Total Current Liabilities	0.18	0.89		-0.21	0.56	0.19	-0.66	-0.03	-0.13	0.63	0.08	0.3	-0.13	-0.31	0.45	0.76	0.77	0.68	0.99	0.42	0.02	0.53	0.52	0.47	0.53	-0.71
Total Stockholder Equity	0.92	0.08	-0.21		-0.24	-0.98	0.48	-0.34	0.99	-0.27	0.0	0.2	0.99	0.28	-0.54	-0.45	-0.03	-0.18	-0.2	-0.47	0.97	-0.54	-0.42	-0.47	0.44	0.47
Property Plant And Equipment Net	0.05	0.61	0.56	-0.24		0.33	-0.31	-0.42	-0.28	0.74	-0.48	0.7	-0.28	-0.22	0.16	0.61	0.48	0.35	0.64	0.22	-0.14	0.62	0.6	-0.03	0.3	-0.14
Net Debt	-0.89	-0.08	0.19	-0.98	0.33		-0.5	0.27	-1.0	0.39	-0.02	-0.15	-1.0	-0.3	0.56	0.45	0.11	0.2	0.2	0.52	-0.97	0.55	0.46	0.47	-0.47	-0.45
Retained Earnings	0.22	-0.35	-0.66	0.48	-0.31	-0.5		-0.51	0.44	-0.52	-0.41	0.14	0.44	0.34	-0.95	-0.82	-0.61	-0.93	-0.69	-0.93	0.35	-0.61	-0.76	-0.88	-0.26	0.85
Accounts Payable	-0.4	-0.41	-0.03	-0.34	-0.42	0.27	-0.51		-0.28	-0.23	0.56	-0.43	-0.28	0.33	0.55	0.27	-0.15	0.37	-0.06	0.46	-0.33	0.28	0.35	0.5	-0.2	-0.34
Cash	0.92	0.13	-0.13	0.99	-0.28	-1.0	0.44	-0.28		-0.33	0.06	0.17	1.0	0.29	-0.52	-0.39	-0.04	-0.14	-0.14	-0.47	0.99	-0.52	-0.41	-0.44	0.51	0.4
Non Current Assets Total	0.05	0.63	0.63	-0.27	0.74	0.39	-0.52	-0.23	-0.33		-0.12	0.47	-0.33	-0.28	0.44	0.53	0.87	0.55	0.7	0.49	-0.2	0.48	0.53	0.42	0.03	-0.5
Non Currrent Assets Other	0.0	-0.19	0.08	0.0	-0.48	-0.02	-0.41	0.56	0.06	-0.12		-0.74	0.06	-0.08	0.51	0.07	0.15	0.39	0.06	0.49	0.03	-0.2	-0.04	0.55	0.07	-0.55
Other Assets	0.37	0.51	0.3	0.2	0.7	-0.15	0.14	-0.43	0.17	0.47	-0.74		0.17	0.36	-0.36	0.27	0.26	0.01	0.34	-0.32	0.25	0.47	0.38	-0.42	0.16	0.27
Cash And Short Term Investments	0.92	0.13	-0.13	0.99	-0.28	-1.0	0.44	-0.28	1.0	-0.33	0.06	0.17		0.29	-0.52	-0.39	-0.04	-0.14	-0.14	-0.47	0.99	-0.52	-0.41	-0.44	0.51	0.4
Common Stock Total Equity	0.15	-0.34	-0.31	0.28	-0.22	-0.3	0.34	0.33	0.29	-0.28	-0.08	0.36	0.29		-0.43	-0.12	-0.38	-0.27	-0.34	-0.45	0.21	0.19	0.1	-0.43	-0.32	0.39
Common Stock Shares Outstanding	-0.36	0.12	0.45	-0.54	0.16	0.56	-0.95	0.55	-0.52	0.44	0.51	-0.36	-0.52	-0.43		0.64	0.5	0.82	0.49	0.99	-0.46	0.45	0.62	0.93	0.1	-0.8
Capital Surpluse	-0.14	0.53	0.76	-0.45	0.61	0.45	-0.82	0.27	-0.39	0.53	0.07	0.27	-0.39	-0.12	0.64		0.48	0.81	0.77	0.61	-0.27	0.86	0.91	0.51	0.35	-0.7
Other Current Assets	0.32	0.77	0.77	-0.03	0.48	0.11	-0.61	-0.15	-0.04	0.87	0.15	0.26	-0.04	-0.38	0.5	0.48		0.69	0.82	0.54	0.09	0.26	0.37	0.58	0.31	-0.65
Other Stockholder Equity	0.11	0.48	0.68	-0.18	0.35	0.2	-0.93	0.37	-0.14	0.55	0.39	0.01	-0.14	-0.27	0.82	0.81	0.69		0.71	0.83	-0.03	0.52	0.74	0.76	0.46	-0.78
Total Liab	0.2	0.89	0.99	-0.2	0.64	0.2	-0.69	-0.06	-0.14	0.7	0.06	0.34	-0.14	-0.34	0.49	0.77	0.82	0.71		0.48	0.02	0.55	0.56	0.47	0.55	-0.69
Property Plant And Equipment Gross	-0.28	0.13	0.42	-0.47	0.22	0.52	-0.93	0.46	-0.47	0.49	0.49	-0.32	-0.47	-0.45	0.99	0.61	0.54	0.83	0.48		-0.4	0.42	0.61	0.9	0.12	-0.76
Total Current Assets	0.97	0.29	0.02	0.97	-0.14	-0.97	0.35	-0.33	0.99	-0.2	0.03	0.25	0.99	0.21	-0.46	-0.27	0.09	-0.03	0.02	-0.4		-0.43	-0.32	-0.39	0.62	0.31
Common Stock	-0.32	0.3	0.53	-0.54	0.62	0.55	-0.61	0.28	-0.52	0.48	-0.2	0.47	-0.52	0.19	0.45	0.86	0.26	0.52	0.55	0.42	-0.43		0.94	0.32	0.0	-0.43
Property Plant Equipment	-0.19	0.29	0.52	-0.42	0.6	0.46	-0.76	0.35	-0.41	0.53	-0.04	0.38	-0.41	0.1	0.62	0.91	0.37	0.74	0.56	0.61	-0.32	0.94		0.45	0.14	-0.51
Other Liab	-0.29	0.18	0.47	-0.47	-0.03	0.47	-0.88	0.5	-0.44	0.42	0.55	-0.42	-0.44	-0.43	0.93	0.51	0.58	0.76	0.47	0.9	-0.39	0.32	0.45		0.01	-0.87
Net Tangible Assets	0.64	0.62	0.53	0.44	0.3	-0.47	-0.26	-0.2	0.51	0.03	0.07	0.16	0.51	-0.32	0.1	0.35	0.31	0.46	0.55	0.12	0.62	0.0	0.14	0.01		-0.14
Net Receivables	0.19	-0.44	-0.71	0.47	-0.14	-0.45	0.85	-0.34	0.4	-0.5	-0.55	0.27	0.4	0.39	-0.8	-0.7	-0.65	-0.78	-0.69	-0.76	0.31	-0.43	-0.51	-0.87	-0.14

Click cells to compare fundamentals

Qualigen Therapeutics Account Relationship Matchups

Qualigen Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	3.7M	29.1M	22.8M	19.1M	2.0M	1.9M
Other Current Liab	2.2M	9.5M	3.3M	7.4M	614.6K	583.9K
Total Current Liabilities	5.3M	10.4M	4.6M	8.6M	4.1M	5.4M
Total Stockholder Equity	(1.9M)	18.3M	16.6M	7.2M	(2.1M)	(2.0M)
Property Plant And Equipment Net	1.7M	1.5M	696.1K	1.8M	1.8M	0.0
Net Debt	2.1M	(23.6M)	(15.9M)	(4.3M)	897.4K	942.3K
Retained Earnings	(47.3M)	(66.8M)	(84.7M)	(103.4M)	(116.8M)	(111.0M)
Accounts Payable	879.3K	500.8K	886.2K	619.6K	2.2M	2.3M
Cash	153.1K	24.0M	17.5M	7.0M	401.8K	381.7K
Non Current Assets Total	2.1M	902.1K	2.0M	8.3M	866.5K	823.2K
Non Currrent Assets Other	(2.1M)	18.3K	18.3K	24.0K	866.5K	909.8K
Other Assets	29.7K	18.3K	18.3K	24.0K	1.0	0.95
Cash And Short Term Investments	153.1K	24.0M	17.5M	7.0M	401.8K	381.7K
Common Stock Total Equity	49.4K	6.0K	19.1K	27.3	24.57	23.34
Common Stock Shares Outstanding	627K	723.7K	2.9M	3.8M	5.1M	5.3M
Liabilities And Stockholders Equity	3.7M	29.1M	22.8M	19.1M	2.0M	1.9M
Other Current Assets	98.4K	2.7M	1.4M	6.1M	765.0K	1.4M
Other Stockholder Equity	45.2M	85.1M	101.3M	110.5M	114.7M	81.5M
Total Liab	5.6M	10.8M	6.3M	10.3M	4.1M	5.9M
Property Plant And Equipment Gross	108.7K	678.12	5.2M	6.5M	7.4M	7.8M
Total Current Assets	1.6M	28.2M	20.8M	10.8M	1.2M	1.1M
Property Plant Equipment	1.5M	696.1K	1.8M	1.8M	2.0M	1.3M
Other Liab	2.7K	158.3K	92.9K	406.8K	467.8K	491.2K
Net Tangible Assets	(2.7M)	18.1M	16.4M	764.4K	879.1K	835.1K
Net Receivables	707.3K	615.8K	822.4K	538.6K	484.7K	588.3K
Inventory	660.1K	953.5K	1.1M	1.6M	1.8M	1.1M

Pair Trading with Qualigen Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Qualigen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Qualigen Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Qualigen Stock

0.65	FDMT	4D Molecular Therapeutics	Pair Corr
0.83	JNJ	Johnson Johnson Sell-off Trend	Pair Corr
0.9	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr

Moving against Qualigen Stock

0.83	BMY	Bristol Myers Squibb Sell-off Trend	Pair Corr
0.8	NAMS	NewAmsterdam Pharma	Pair Corr
0.63	PMVP	Pmv Pharmaceuticals	Pair Corr
0.61	PHVS	Pharvaris BV	Pair Corr
0.43	LPTX	Leap Therapeutics	Pair Corr

The ability to find closely correlated positions to Qualigen Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Qualigen Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Qualigen Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Qualigen Therapeutics to buy it.

The correlation of Qualigen Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Qualigen Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Qualigen Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Qualigen Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Qualigen Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Qualigen Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Qualigen Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Qualigen Therapeutics Stock:

How To Invest In Qualigen

Details

Is Qualigen Stock a good investment?

Details

What is Qualigen Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Qualigen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.

You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Qualigen Therapeutics. If investors know Qualigen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Qualigen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

3.6 K

Revenue Per Share

1.034

Quarterly Revenue Growth

0.137

Return On Assets

(0.75)

Return On Equity

(8.42)

The market value of Qualigen Therapeutics is measured differently than its book value, which is the value of Qualigen that is recorded on the company's balance sheet. Investors also form their own opinion of Qualigen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Qualigen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Qualigen Therapeutics' market value can be influenced by many factors that don't directly affect Qualigen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Qualigen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Qualigen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Qualigen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Qualigen Short Long Term Debt vs Long Term Debt Analysis

Short Long Term Debt vs Long Term Debt

Short Long Term Debt vs Long Term Debt Correlation Analysis

Correlation Coefficient

Short Long Term Debt

Long Term Debt

Qualigen Therapeutics fundamental ratios Correlations

Qualigen Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Qualigen Therapeutics fundamental ratios Accounts

Pair Trading with Qualigen Therapeutics

Moving together with Qualigen Stock

Moving against Qualigen Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 0.99	Total Current Liabilities
Cash	+ 0.99	Total Stockholder Equity
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 0.98	Total Stockholder Equity
Total Current Assets	- 0.97	Net Debt
Common Stock Shares Outstanding	- 0.95	Retained Earnings
Property Plant And Equipment Gross	- 0.93	Retained Earnings